Latest 10-K annual reports

Crimson Wine Group, Ltd. reported a significant decrease in net sales and operating income for fiscal year 2025, driven by challenging market conditions and a goodwill impairment charge, despite a strategic acquisition post-year-end.

Brilliant Earth Group, Inc. reported a net loss of $6.4 million for 2025, a significant decline from the prior year's net income, despite a 3.6% increase in net sales to $437.5 million.

GitLab Inc. announced robust 26% revenue growth to $955.2 million for fiscal year 2026, alongside a significant shift to positive operating cash flow and adjusted free cash flow, despite an increased net loss.

Ankam, Inc. reported a significant increase in revenue and a reduced net loss for fiscal year 2025, driven by Asian market expansion, despite ongoing going concern issues and material weaknesses in internal controls.

Lululemon Athletica Inc. reports 5% net revenue growth in 2025, driven by strong international performance, despite a decline in Americas sales and a significant impact from increased tariffs.

Fold Holdings, a bitcoin-focused financial services company, reported a 34% increase in net revenue for 2025, but also a significant rise in operating and net losses, alongside new product launches and debt restructuring.

NextNav Inc. reported a significant increase in net losses and a decrease in revenue for fiscal year 2025, as it continues to invest heavily in its NextGen 5G positioning, navigation, and timing solutions and seeks critical FCC approvals.

IZEA Worldwide, Inc. reported net income of $42,326 for the fiscal year ended December 31, 2025, marking a significant turnaround from a $18.85 million net loss in 2024, driven by strategic cost reductions and a focus on core enterprise customers.

Farmers National Banc Corp. filed an amendment to its 2025 Annual Report on Form 10-K to include its policy on recovery of erroneously awarded compensation.

HealthEquity, Inc. announced robust financial results for the fiscal year ended January 31, 2026, driven by significant increases in HSA assets and net income, alongside strategic technology investments and operational efficiencies.

BlackSky Technology Inc. reported a 4.4% revenue increase to $106.6 million for fiscal year 2025, driven by strong mission solutions, but saw net losses widen to $70.3 million and Adjusted EBITDA decline significantly.

Gossamer Bio announced a workforce reduction and missed the primary endpoint in its Phase 3 PROSERA trial for seralutinib, leading to strategic re-evaluation and a need for additional capital.

Academy Sports and Outdoors reported a 2.0% net sales increase to $6.05 billion for fiscal year 2025, but saw a 1.5% decline in comparable sales and a 10.0% drop in net income.

Longeveron Inc. reported a widened net loss for fiscal year 2025 and substantial doubt about its ability to continue as a going concern, despite advancing its lead product candidate, laromestrocel, in multiple clinical programs.

Kalaris Therapeutics, a clinical-stage biopharmaceutical company, reported significant net losses in 2025 while advancing its lead product candidate, TH103, for retinal diseases with promising early clinical data.

The Mosaic Company filed an amendment to its 2025 annual report to include omitted shareholder data and a revised consent for its Esterhazy Potash Facility.

Idaho Copper Corporation reported continued net losses and a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern, despite progress on its CuMo Project exploration permits.

Gap Inc. reported a 2% increase in net sales to $15.4 billion for fiscal 2025, alongside a slight decline in net income and diluted EPS, as it continues strategic transformation amidst a challenging macroeconomic environment.

Groovy Company's 2025 Annual Report details significant progress on its OTCM Protocol blockchain platform, despite ongoing financial challenges and a need for substantial capital.

MGT Capital Investments, Inc. has ceased active cryptocurrency mining and hosting operations, sold its primary facility, and is now evaluating strategic alternatives amidst significant going concern uncertainties.

Comstock Holding Companies, Inc. announced significant revenue and net income growth for fiscal year 2025, driven by managed portfolio expansion and strategic investments.

Lifeway Foods, Inc. announced a significant increase in net sales and net income for fiscal year 2025, alongside key corporate governance changes and strategic investments.

Expion360 Inc. reported a 71.6% increase in net sales for 2025, reaching $9.7 million, despite continued net losses and an ongoing 'going concern' qualification from auditors.

Lake Shore Bancorp, Inc. reported a significant increase in net income and improved asset quality for 2025, following its successful second-step conversion and strategic focus on commercial lending and core deposit growth.

Neuronetics, Inc. announced significant revenue growth for 2025, driven by the Greenbrook acquisition, alongside a new CEO appointment and ongoing efforts to improve profitability.

Abeona Therapeutics Inc. reports FDA approval for ZEVASKYN, generating significant revenue from a Priority Review Voucher sale, while continuing to advance its gene therapy pipeline.

PSQ Holdings, Inc. announced a strategic pivot to focus solely on its Financial Technology segment, reporting reduced net losses for 2025, but faces a NYSE delisting notice due to non-compliance with listing standards.

Bicycle Therapeutics reported increased net losses in 2025 and announced a strategic reprioritization of its clinical pipeline, including discontinuing certain trials and a 30% workforce reduction, to focus on next-generation therapeutics.

Monte Rosa Therapeutics reported significant progress in its molecular glue degrader pipeline, including positive clinical data for MRT-2359 and MRT-8102, and strengthened its financial position with a $323.8 million capital raise.

Clene Inc. reports strong clinical data for its lead drug candidate CNM-Au8 in ALS, paving the way for an accelerated FDA approval pathway by mid-2026, despite ongoing financial challenges.